Nightingale Health Plc

Press release

27 June 2024 at 2:45 p.m. (EEST)

Nightingale Health Plc, a pioneer in disease risk detection and preventative health, announced it has acquired all intellectual property assets from RenegadeXBio, PBC related to the Velvet™ blood collection device.

The acquisition of the intellectual property assets, previously owned by Weavr Health Corp, changes Nightingale Health’s position from license holder to having the full and exclusive ownership and control over the Velvet™ device.

High quality blood self-collection capability is a strategic component in enabling global delivery of Nightingale Health’s services. Nightingale Health uses the Velvet™ blood collection device in its Remote Health Check, providing an industry-leading panel of blood biomarkers and disease risk detection for the most common chronic diseases from a blood sample collected anywhere, for example at home, without the need to visit a laboratory.

Nightingale’s Remote Health Check offers unparalleled benefits, including a market-leading sample preservation time of several weeks, clinical-grade multi-disease risk detection capability, and the most extensive blood biomarker panel available. This combination sets it far ahead of any competing solutions. Furthermore, in real-world consumer usage the Velvet™ blood collection device has an impressive success rate of over 95%.

“We have been systematically investing to integrate the Velvet™ device tightly as a part of our end-to-end solutions, and acquiring the ownership and full control of the intellectual property assets without any limitations was an important part of executing this strategy” says Teemu Suna, CEO and Founder of Nightingale Health. “We have several years’ experience of the performance of the Velvet™ device, and we are confident that it continues to be the best remote blood collection solution available with clinical grade quality. This acquisition secures our position as the sole provider of a fully integrated remote blood test and health check solution, encompassing the proprietary blood collection device, advanced blood analysis technology, and comprehensive disease risk analysis” Suna continues.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com